AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2894357 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine alone
Number of subjects: 114
Study 2894357 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine alone or in combination with hydrochlorothiazide or propranolol or both
Number of subjects: 114
Study 29241976 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-congruent apologies (female physicians providing affective apologies, male physicians providing cognitive apologies)
Number of subjects: 0
Study 29241976 — intervention group
Group type: COMPARATOR
Intervention: Gender-incongruent apologies (female physicians providing cognitive apologies, male physicians providing affective apologies)
Number of subjects: 0
Study 27356698 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimented with smoking
Number of subjects: 326
Study 27356698 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 326
Study 27356698 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for a cigarette first thing in the morning
Number of subjects: 326
Study 27356698 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking initiation related to age
Number of subjects: 326
Study 27356698 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking initiation related to gender and living situation
Number of subjects: 326
Study 27356698 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking initiation related to substance use
Number of subjects: 326
Study 27356698 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers related to alcohol consumption
Number of subjects: 326
Study 24796987 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA (Clarinol A‐80; n = 17)
Number of subjects: 33
Study 24796987 — intervention group
Group type: COMPARATOR
Intervention: PLA (sunflower oil; n = 16)
Number of subjects: 33
Study 24796987 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA
Number of subjects: 33
Study 24796987 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 33
Study 22628663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate vaginal flora (IVF)
Number of subjects: 1367
Study 22628663 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (BV)
Number of subjects: 1367
Study 22628663 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV
Number of subjects: 1367
Study 19896172 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard urotherapy combined with biofeedback therapy (Group 1)
Number of subjects: 94
Study 19896172 — intervention group
Group type: COMPARATOR
Intervention: Standard urotherapy only (Group 2)
Number of subjects: 94
Study 18612862 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based clinician-assisted computerized cognitive behavioural therapy programme
Number of subjects: 105
Study 18612862 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 105
Study 16102630 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD Express
Number of subjects: 30
Study 16102630 — intervention group
Group type: COMPARATOR
Intervention: SCD Response
Number of subjects: 30
Study 11919228 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete mesorectum
Number of subjects: 180
Study 11919228 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete mesorectum
Number of subjects: 180
Study 10376129 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 10
Study 10376129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8726300 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 34
Study 8726300 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 34
Study 8726300 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 34
Study 8726300 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (after 7 days)
Number of subjects: 34
Study 1686080 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency TENS (2 Hz)
Number of subjects: 37
Study 1686080 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency TENS (100 Hz)
Number of subjects: 37
Study 7131540 — intervention group
Group type: EXPERIMENTAL
Intervention: High-status experimenter
Number of subjects: 40
Study 7131540 — intervention group
Group type: COMPARATOR
Intervention: Equal-status experimenter
Number of subjects: 40
Study 31606445 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan plus fludarabine
Number of subjects: 476
Study 31606445 — intervention group
Group type: COMPARATOR
Intervention: Busulfan plus fludarabine
Number of subjects: 476
Study 31493209 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention group
Number of subjects: 140
Study 31493209 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study 28809990 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% spray
Number of subjects: 297
Study 28809990 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.05% spray
Number of subjects: 297
Study 28809990 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol 0.05% spray
Number of subjects: 297
Study 28809990 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 297
Study 28809990 — intervention group
Group type: COMPARATOR
Intervention: 0.1% sodium lauryl sulfate
Number of subjects: 297
Study 28809990 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 297
Study 28809990 — intervention group
Group type: COMPARATOR
Intervention: Active comparator control (clobetasol spray)
Number of subjects: 297
Study 25643851 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized mailed feedback outlining specific risks associated with alcohol use, an educational booklet on alcohol and aging, and the National Institutes of Health Rethinking Drinking: Alcohol and Your Health booklet
Number of subjects: 86
Study 25643851 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 86
Study 24535654 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 80
Study 24535654 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 80
Study 22305243 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile Massage (TM)
Number of subjects: 53
Study 22305243 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Exercises
Number of subjects: 53
Study 19099314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin preoperatively
Number of subjects: 58
Study 19099314 — intervention group
Group type: COMPARATOR
Intervention: Placebo preoperatively
Number of subjects: 58
Study 17993363 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (psychoeducational group, treatment adherence support, pharmacotherapy if needed)
Number of subjects: 230
Study 17993363 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 230
Study 17993363 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 230
Study 15316713 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65 g alcohol/kg
Number of subjects: 32
Study 15316713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12490789 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose CsA plus concentration-controlled SRL (troughs 10-20 ng/mL; group B, n=100)
Number of subjects: 246
Study 12490789 — intervention group
Group type: COMPARATOR
Intervention: Full-dose CsA (microemulsion) plus fixed-dose SRL (2 mg/day; group A, n=97)
Number of subjects: 246
Study 9661093 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral electroconvulsive therapy (ECT)
Number of subjects: 1
Study 14689023 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline sulphate (dry powder, Turbuhaler - 0.5 mg)
Number of subjects: 47
Study 14689023 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline sulphate (nebulizer 1% solution in saline - compressed air 6 l/min)
Number of subjects: 47
Study 3745846 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide 10 mg q.i.d.
Number of subjects: 23
Study 3745846 — intervention group
Group type: EXPERIMENTAL
Intervention: domperidone 20 mg q.i.d.
Number of subjects: 23
Study 3745846 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study 31971424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 183
Study 31718386 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified attention training
Number of subjects: 98
Study 31718386 — intervention group
Group type: COMPARATOR
Intervention: Placebo program
Number of subjects: 98
Study 31718386 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 98
Study 30326940 — intervention group
Group type: EXPERIMENTAL
Intervention: Homotopic noxious stimulation group (group A)
Number of subjects: 144
Study 30326940 — intervention group
Group type: EXPERIMENTAL
Intervention: Homotopic innocuous stimulation group (group B)
Number of subjects: 144
Study 30326940 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterotopic noxious stimulation group (group C)
Number of subjects: 144
Study 30326940 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterotopic innocuous stimulation group (group D)
Number of subjects: 144
Study 30326940 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 144
Study 26945570 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year group-based behavioral intervention designed to achieve and maintain weight loss
Number of subjects: 692
Study 26945570 — intervention group
Group type: COMPARATOR
Intervention: Less intensive control intervention
Number of subjects: 692
Study 22696251 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior cyclophosphamide
Number of subjects: 49
Study 22696251 — intervention group
Group type: COMPARATOR
Intervention: Prior docetaxel
Number of subjects: 49
Study 22502848 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise programme
Number of subjects: 27
Study 22502848 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 20434400 — intervention group
Group type: EXPERIMENTAL
Intervention: EIA plus regional hyperthermia
Number of subjects: 341
Study 20434400 — intervention group
Group type: COMPARATOR
Intervention: EIA alone
Number of subjects: 341
Study 18324951 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly (OW)
Number of subjects: 0
Study 18324951 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 35 mg once weekly (OW)
Number of subjects: 0
Study 18207124 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin + topical prednisolone phosphate
Number of subjects: 42
Study 18207124 — intervention group
Group type: COMPARATOR
Intervention: Topical moxifloxacin + placebo
Number of subjects: 42
Study 15381937 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² plus Epirubicin 75 mg/m² (ET)
Number of subjects: 142
Study 15381937 — intervention group
Group type: COMPARATOR
Intervention: 5-Fluorouracil 500 mg/m² plus Epirubicin 75 mg/m² and Cyclophosphamide 500 mg/m² (FEC)
Number of subjects: 142
Study 11416804 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinestherapy and inhaled bronchodilator drugs (salbutamol and/or ipratropium bromide) with a boreal nebulizer, bronchial hygiene, breathing exercises on a Bodyguard Ergometer 990, treated three times per week for twelve weeks.
Number of subjects: 38
Study 9304426 — intervention group
Group type: EXPERIMENTAL
Intervention: Family physician involvement with a fail-safe system for follow-up
Number of subjects: 0
Study 9304426 — intervention group
Group type: COMPARATOR
Intervention: Family physician involvement without a fail-safe system for follow-up
Number of subjects: 0
Study 9304426 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall compliance in the study group
Number of subjects: 0
Study 8439686 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosyn
Number of subjects: 10
Study 8439686 — intervention group
Group type: EXPERIMENTAL
Intervention: FreAmine HBC
Number of subjects: 10
Study 8439686 — intervention group
Group type: EXPERIMENTAL
Intervention: TrophAmine
Number of subjects: 10
Study 3790399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol consumption (66 g per day)
Number of subjects: 8
Study 3790399 — intervention group
Group type: COMPARATOR
Intervention: Control (abstained from ethanol for 4 days)
Number of subjects: 8
Study 31065365 — intervention group
Group type: EXPERIMENTAL
Intervention: CWE (chromoendoscopy with water exchange)
Number of subjects: 480
Study 31065365 — intervention group
Group type: EXPERIMENTAL
Intervention: WE (water exchange)
Number of subjects: 480
Study 31065365 — intervention group
Group type: COMPARATOR
Intervention: AI (air insufflation)
Number of subjects: 480
Study 31065365 — intervention group
Group type: EXPERIMENTAL
Intervention: CWE
Number of subjects: 480
Study 31065365 — intervention group
Group type: EXPERIMENTAL
Intervention: WE
Number of subjects: 480
Study 31065365 — intervention group
Group type: COMPARATOR
Intervention: AI
Number of subjects: 480
Study 30157826 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive Function (EF) training
Number of subjects: 0
Study 30157826 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study 26653612 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide MR 60 mg once daily (FIRST group)
Number of subjects: 7170
Study 26653612 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide MR 60 mg once daily (ADD group)
Number of subjects: 7170
Study 26653612 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide MR 60 mg once daily (SWITCH group)
Number of subjects: 7170
Study 26653612 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide MR 60 mg once daily
Number of subjects: 7170
Study 25439972 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT), 8 sessions of 2 hours each
Number of subjects: 33
Study 25439972 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study 22395580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 3117
Study 22395580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 3117
Study 19156087 — intervention group
Group type: EXPERIMENTAL
Intervention: Stalevo (levodopa/carbidopa/entacapone)
Number of subjects: 34
Study 17227219 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH(1-34) 50 microg daily subcutaneously for 1 month
Number of subjects: 27
Study 17227219 — intervention group
Group type: COMPARATOR
Intervention: Control group (13 postmenopausal women with osteoporosis)
Number of subjects: 27
Study 15471657 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Interference Estimate (FIE)
Number of subjects: 1337
Study 11396815 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (1.5 mg retinyl palmitate and 30 mg beta-carotene daily during pregnancy plus 60 mg retinyl palmitate at delivery)
Number of subjects: 238
Study 11396815 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 238
Study 11396815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 9594475 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish application
Number of subjects: 316
Study 9594475 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish application
Number of subjects: 316
Study 8053282 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg OD
Number of subjects: 91
Study 8053282 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg OD
Number of subjects: 91
Study 8053282 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg with diuretics
Number of subjects: 91
Study 8053282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurements
Number of subjects: 91
Study 8053282 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 91
Study 8053282 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 91
Study 2898244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) (2 mg/day)
Number of subjects: 186
Study 2898244 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate (GST) (50 mg/week)
Number of subjects: 186
Study 2898244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 186
Study 31599809 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SCRT) + total mesorectal excision (TME) in high-risk patients (HiR)
Number of subjects: 401
Study 31599809 — intervention group
Group type: COMPARATOR
Intervention: TME alone in high-risk patients (HiS)
Number of subjects: 401
Study 31599809 — intervention group
Group type: EXPERIMENTAL
Intervention: SCRT + TME in low-risk patients (LoR)
Number of subjects: 401
Study 31599809 — intervention group
Group type: COMPARATOR
Intervention: TME alone in low-risk patients (LoS)
Number of subjects: 401
Study 31599809 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk patients (LoR)
Number of subjects: 401
Study 31599809 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients (HiR)
Number of subjects: 401
Study 29659969 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg aspartame/d
Number of subjects: 100
Study 29659969 — intervention group
Group type: EXPERIMENTAL
Intervention: 1050 mg aspartame/d
Number of subjects: 100
Study 29659969 — intervention group
Group type: COMPARATOR
Intervention: 0 mg aspartame/d (control group)
Number of subjects: 100
Study 27271754 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cruciate substitution (PS)
Number of subjects: 61
Study 27271754 — intervention group
Group type: COMPARATOR
Intervention: Posterior cruciate retention (CR)
Number of subjects: 61
Study 26148063 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis before skin incision
Number of subjects: 410
Study 26148063 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prophylaxis after umbilical cord clamping
Number of subjects: 410
Study 23704120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone intervention (CPI)
Number of subjects: 474
Study 23704120 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 474
Study 21154195 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (83 μg or 3,332 IU daily for 1 year)
Number of subjects: 54
Study 21154195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 18506636 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography angiography (CTA)
Number of subjects: 21
Study 16818837 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care rapid influenza test
Number of subjects: 468
Study 16818837 — intervention group
Group type: COMPARATOR
Intervention: No rapid influenza test
Number of subjects: 468
Study 21904686 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg
Number of subjects: 6
Study 21904686 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 8 mg
Number of subjects: 6
Study 21904686 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (2 mg and 8 mg)
Number of subjects: 6
Study 21904686 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin
Number of subjects: 6
Study 21904686 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 6
Study 21904686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 10516884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.75 mg/d
Number of subjects: 16
Study 10516884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 4.5 mg/d
Number of subjects: 16
Study 10516884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7863370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 0
Study 2328559 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine treatment
Number of subjects: 15
Study 7011249 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose haloperidol
Number of subjects: 20
Study 7011249 — intervention group
Group type: COMPARATOR
Intervention: Low-dose haloperidol
Number of subjects: 20
Study 30448517 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb
Number of subjects: 20
Study 30448517 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 28705208 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly audit and feedback interventions with different comparators and framing
Number of subjects: 56000
Study 28705208 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 56000
Study 27140801 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombomodulin alfa (0.06 mg/kg)
Number of subjects: 368
Study 27140801 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombomodulin alfa (0.02 mg/kg)
Number of subjects: 368
Study 23471208 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (30 g/d)
Number of subjects: 69
Study 23471208 — intervention group
Group type: COMPARATOR
Intervention: Placebo (casein, 30 g/d)
Number of subjects: 69
Study 21419356 — intervention group
Group type: EXPERIMENTAL
Intervention: Greek traditional dance courses and upper body training (1 hour, 3 sessions/week) for 24 weeks
Number of subjects: 27
Study 19725255 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 60
Study 19725255 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 60
Study 17692748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (2 mg/kg) alone
Number of subjects: 22
Study 17692748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 22
Study 17692748 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 22
Study 15462544 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic Growth Inventory (PTGI) linked to a specific stressful event
Number of subjects: 276
Study 15462544 — intervention group
Group type: COMPARATOR
Intervention: Posttraumatic Growth Inventory (PTGI) not linked to specific events
Number of subjects: 276
Study 11232690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg b.i.d.
Number of subjects: 1273